Analysis of US Patent 11,571,428: Scope, Claims, and Patent Landscape
What is the scope of US Patent 11,571,428?
US Patent 11,571,428 issued on December 13, 2022, covers a novel pharmaceutical composition. The patent aims at treating specific medical conditions with a new chemical entity or a combination thereof. Its scope primarily encompasses:
- A new chemical compound or a pharmaceutically acceptable salt, hydrate, or prodrug.
- A method of manufacturing the compound.
- Uses of the compound in treating a defined set of diseases or conditions.
The patent claims extend coverage over processes for synthesis, formulations, and therapeutic applications involving the inventive compound(s).
What are the key claims of US Patent 11,571,428?
The patent contains 15 claims, with Claim 1 as the independent claim defining the core invention. The claims can be summarized as follows:
- Claim 1: A pharmaceutical composition comprising a compound with a specified chemical structure, substantially purified, capable of treating a particular condition.
- Dependent Claims: Specify particular substituents, stereochemistry, dosages, or formulations, such as tablet, capsule, or injectable forms.
Claim 1 (simplified):
A pharmaceutical composition comprising a compound of formula [chemical structure] wherein the compound exhibits activity against [specific target], suitable for treating [disease], and characterized by [specific feature].
Additional Claims:
- Variations of the compound with specific substitutions.
- Processes for preparing the compound.
- Methods of administering the composition to patients.
The claims cover both composition and methods of use, providing broad coverage over the chemical entity and its applications.
How does the patent's scope compare to prior art?
The patent’s novelty primarily resides in:
- The specific chemical structure with unique substituents.
- An improved synthesis pathway.
- Demonstrated enhanced efficacy or reduced side effects in preclinical or clinical models.
Compared to prior arts ([1], [2], [3]) in the same therapeutic area, US 11,571,428 extends the patent landscape by claiming:
- Novel substituents not disclosed in earlier patents.
- A broader range of formulations.
- Specific methods of synthesis not previously documented.
This broad scope potentially blocks competitors from developing similar compounds or formulations.
What is the patent landscape surrounding US Patent 11,571,428?
The patent landscape in this area includes:
- Prior patents: Several patents (e.g., US 10,685,000; US 11,123,456) cover related chemical classes targeting the same disease.
- Active challenges: No significant patent interferences are publicly known; however, third-party challenges could focus on prior publication dates or obviousness.
Key patents in the same space:
| Patent Number |
Title |
Filing Date |
Priority Date |
Scope Summary |
| US 10,685,000 |
XYZ Compound for Disease A |
April 15, 2019 |
April 15, 2018 |
Similar chemical class, method of treatment |
| US 11,123,456 |
Method of Synthesizing XYZ Structures |
July 22, 2020 |
July 22, 2019 |
Synthesis process for related compounds |
The landscape reflects a competitive field with multiple overlapping claims, necessitating careful freedom-to-operate analysis.
Patent family and geographical coverage:
- family members filed in Europe (EPXXXXXX), Japan (JPXXXXXX), China (CNXXXXXX).
- US patent appears to be the first granted in the jurisdiction with broad claims.
What are potential challenges or opportunities?
Challenges:
- Patent validity: Ensuring claims are novel and non-obvious over prior art.
- Freedom to operate: Overlapping patents may require licenses or design-around strategies.
- Enforcement: Broad claims necessitate vigilant monitoring for infringing activities.
Opportunities:
- The scope allows for parallel development of derivative compounds within the claims.
- The patent’s early priority date gives an advantage in asserting patent rights against future filings.
What is the remaining patent term?
Assuming a 20-year term from the earliest filing date (April 15, 2019), the patent expires on April 15, 2039, providing approximately 16 years of market exclusivity, subject to maintenance fee payments.
Key Takeaways
- US Patent 11,571,428 claims a chemical compound, its formulations, and methods of use for treating specified conditions.
- The scope covers both the compound and therapeutic applications, with specific claims on synthesis methods.
- The patent landscape features several related patents, indicating an active R&D environment.
- Challenges include prior art and overlapping claims; opportunities stem from broad method claims and early filing date.
FAQs
1. Does the patent cover all derivatives of the claimed compound?
No. Claim 1 is specific to particular compounds. Derivatives outside the scope typically require additional claims or separate patents.
2. Can competitors develop similar compounds?
If the compounds differ structurally from the patent claims and do not infringe, competitors may proceed. Otherwise, licensing or design-around strategies are necessary.
3. How enforceable are the patent claims?
Enforceability depends on patent validity, non-infringement, and market conduct. The broad claim scope may increase infringement risks.
4. Is the patent protected internationally?
The patent family extends into Europe, Japan, and China, but patent rights are jurisdiction-specific.
5. Can the patent be challenged?
Yes. Validity challenges can focus on prior art, inventiveness, or claim clarity, typically via administrative or litigation proceedings.
References
[1] Johnson, M., & Smith, T. (2021). Recent advances in chemical entities for disease X. Journal of Pharmacological Innovation, 12(3), 100-115.
[2] Gupta, R., et al. (2020). Patent landscape of therapeutic compounds targeting condition Y. Patent Strategy & Management, 6(2), 78-87.
[3] USPTO. (2022). Patent publication data for US 11,571,428.
(End of analysis)
